Study Comparing Empagliflozin, Acetazolamide, and Metolazone Added to Loop Diuretics for Treating Acute Decompensated Heart Failure

What this Trial Is About

Researchers are comparing the effectiveness and safety of three add-on drugsempagliflozin, acetazolamide, and metolazonewhen given with loop diuretics to patients hospitalized with acute decompensated heart failure. This phase 2 clinical trial aims to understand which of these treatments best supports fluid removal and heart failure management in this patient group. The study includes three groups of 22 patients each. One group receives 10 mg of empagliflozin, another 500 mg of acetazolamide, and the third 5 mg of metolazone. Each drug is given orally alongside the first dose of loop diuretics daily for three days. The trial does not use placebos and participants are randomly assigned to one of the three treatment groups. Participants will be closely monitored during the three-day treatment period with measurements such as total urine output and changes in specific blood and urine biomarkers related to heart failure. Researchers will also track 30-day mortality rates and assess treatment effectiveness using the ADVOR Score. This monitoring helps evaluate the safety and impact of these add-on therapies over the short term and up to 30 days after treatment begins.

Add-on Diuretics in Acute Decompensated Heart Failure